About Hemispherx BioPharma (NYSEAMERICAN:HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs
Trailing P/E Ratio-1.88571428571429
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-49.30%
Return on Assets-32.57%
Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions
What is Hemispherx BioPharma's stock symbol?
Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."
How were Hemispherx BioPharma's earnings last quarter?
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings data on Wednesday, November, 15th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $0.09 million during the quarter. Hemispherx BioPharma had a negative return on equity of 49.30% and a negative net margin of 1,391.11%. View Hemispherx BioPharma's Earnings History.
Are investors shorting Hemispherx BioPharma?
Hemispherx BioPharma saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,118,922 shares, an increase of 13.7% from the January 12th total of 1,864,347 shares. Based on an average daily volume of 1,222,934 shares, the days-to-cover ratio is currently 1.7 days. Approximately 7.0% of the shares of the stock are sold short.
Who are some of Hemispherx BioPharma's key competitors?
Some companies that are related to Hemispherx BioPharma include Celsion (CLSN), Anthera Pharmaceuticals (ANTH), Egalet (EGLT), Microbot Medical (MBOT), Kitov Pharmaceuticals (KTOV), Eleven Biotherapeutics (EBIO), Vical (VICL), Akari Therapeutics (AKTX), Lipocine (LPCN), Orexigen Therapeutics (OREX), ContraVir Pharmaceuticals (CTRV), Vaxart (VXRT), Aradigm (ARDM), Biopharmx (BPMX), Midatech Pharma (MTPH), Xenetic Biosciences (XBIO), Redx Pharma (REDX) and Ritter Pharmaceuticals (RTTR).
Who are Hemispherx BioPharma's key executives?
Hemispherx BioPharma's management team includes the folowing people:
- William M. Mitchell, Chairman of the Board (Age 81)
- Thomas K. Equels Esq., Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel (Age 64)
- Adam Pascale CPA, Chief Financial Officer (Age 68)
- Wayne Steven Springate, Senior Vice President - Operations (Age 45)
- David R. Strayer M.D., Chief Scientific & Medical Officer (Age 70)
- Peter W. Rodino III, Esq., Executive Director - Governmental Relations, General Counsel (Age 65)
- Stewart L. Appelrouth, Director
How do I buy Hemispherx BioPharma stock?
Shares of Hemispherx BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hemispherx BioPharma's stock price today?
One share of Hemispherx BioPharma stock can currently be purchased for approximately $0.53.
How big of a company is Hemispherx BioPharma?
Hemispherx BioPharma has a market capitalization of $18.30 million.
How can I contact Hemispherx BioPharma?
Hemispherx BioPharma's mailing address is One Penn Center 1617 Jfk Blvd, Suite #500, PHILADELPHIA, PA 19103, United States. The specialty pharmaceutical company can be reached via phone at +1-215-9880080.
MarketBeat Community Rating for Hemispherx BioPharma (HEB)MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hemispherx BioPharma (NYSEAMERICAN:HEB) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Hemispherx BioPharma (NYSEAMERICAN:HEB) Earnings History and Estimates Chart
Hemispherx BioPharma (NYSEAMERICAN HEB) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2017||Q3 2017||($0.04)||$0.09 million||View||N/A|
|8/14/2017||Q2 2017||($0.08)||$0.21 million||View||N/A|
|5/15/2017||Q1 2017||($0.11)||$0.08 million||View||N/A|
|3/31/2017||Q4 2016||($0.04)||$0.02 million||View||N/A|
|11/14/2016||Q3 16||($0.30)||$0.02 million||View||N/A|
|5/16/2016||Q116||($0.01)||$40.99 million||$0.04 million||View||N/A|
|3/29/2016||Q4 2015||($0.12)||$0.03 million||View||N/A|
|11/17/2015||Q3 2015||($0.24)||$0.02 million||View||N/A|
|5/13/2015||Q1 15||($0.02)||$0.04 million||View||N/A|
|3/20/2015||Q4 2014||($0.24)||$0.04 million||View||N/A|
|11/10/2014||Q3 2014||($0.24)||$0.05 million||View||N/A|
|8/11/2014||Q2 2014||($0.36)||$0.04 million||View||N/A|
|5/9/2014||Q1 2014||($0.24)||$0.08 million||View||N/A|
|3/14/2014||Q4 2013||($0.24)||$0.04 million||View||N/A|
|11/8/2013||Q3 2013||($0.36)||$0.04 million||View||N/A|
|8/9/2013||Q2 2013||($0.03)||$0.04 million||View||N/A|
|5/8/2013||Q1 2013||($0.24)||$0.04 million||View||N/A|
Hemispherx BioPharma (NYSEAMERICAN:HEB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Hemispherx BioPharma (NYSEAMERICAN:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com
Hemispherx BioPharma (NYSEAMERICAN HEB) Insider Trading and Institutional Ownership History
Hemispherx BioPharma (NYSEAMERICAN HEB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/2/2017||Adam Pascale||CFO||Buy||15,873||$0.63||$9,999.99||27,389|| |
|5/2/2017||David R Strayer||Insider||Buy||7,937||$0.63||$5,000.31||41,804|| |
|4/27/2017||Thomas K Equels||CEO||Buy||72,464||$0.69||$50,000.16||492,919|| |
|4/11/2017||Thomas K Equels||CEO||Buy||200,000||$0.50||$100,000.00||420,455|| |
|2/16/2017||Adam Pascale||CFO||Buy||6,981||$0.46||$3,211.26||11,516|| |
|2/16/2017||David R Strayer||Insider||Buy||9,892||$0.46||$4,550.32||33,867|| |
|2/16/2017||Wayne S Springate||SVP||Buy||8,014||$0.46||$3,686.44||31,989|| |
|12/22/2016||Thomas K Equels||CEO||Buy||68,493||$0.73||$49,999.89||220,455|| |
|11/1/2016||Thomas K Equels||CEO||Buy||10,000||$1.00||$10,000.00||151,962|| |
|7/8/2016||Thomas K Equels||CEO||Buy||48,000||$0.12||$5,760.00||1,703,548|| |
|7/1/2016||Thomas K Equels||CEO||Buy||171,000||$0.12||$20,520.00||1,514,548|| |
|3/18/2016||Thomas K Equels||CEO||Buy||30,000||$0.13||$3,900.00||1,484,548|| |
|3/11/2016||Thomas K Equels||CEO||Buy||40,000||$0.16||$6,400.00||1,444,548|| |
|3/10/2016||Thomas K Equels||CEO||Buy||30,000||$0.16||$4,800.00||30,000|| |
|8/20/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00||1,225,585|| |
|8/18/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00||1,200,585|| |
|8/17/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00|| |
|8/14/2015||Thomas K Equels||CFO||Buy||79,104||$0.18||$14,238.72|| |
|4/28/2015||William A Carter||CEO||Buy||100,000||$0.24||$24,000.00|| |
|4/27/2015||Thomas K Equels||CFO||Buy||100,000||$0.24||$24,000.00|| |
|4/21/2015||William A Carter||CEO||Buy||100,000||$0.24||$24,000.00|| |
|4/20/2015||Thomas K Equels||CFO||Buy||100,000||$0.24||$24,000.00|| |
|4/17/2015||William A Carter||CEO||Buy||73,681||$0.23||$16,946.63|| |
|4/16/2015||William A Carter||CEO||Buy||26,319||$0.23||$6,053.37|| |
|4/15/2015||Thomas K Equels||CFO||Buy||100,000||$0.23||$23,000.00|| |
Hemispherx BioPharma (NYSEAMERICAN HEB) News Headlines
|Technical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBio - PR Newswire (press release)|
www.prnewswire.com - February 10 at 3:40 PM
|Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 13.7%|
www.americanbankingnews.com - February 9 at 8:06 PM
|Longtime Philadelphia biotech firm leaves the city|
www.bizjournals.com - January 31 at 3:38 PM
|Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs|
finance.yahoo.com - January 31 at 8:52 AM
|Hemispherx to Present at the BIO CEO & Investor Conference|
finance.yahoo.com - January 29 at 8:49 AM
|Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection|
finance.yahoo.com - January 26 at 3:38 PM
|Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint ... - Nasdaq|
www.nasdaq.com - January 25 at 3:39 PM
|Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors|
finance.yahoo.com - January 25 at 8:45 AM
|Hemispherx BioPharma, Inc (HEB) Sees Large Growth in Short Interest|
www.americanbankingnews.com - January 24 at 6:08 PM
|HEB: Recent Advancements…What Do They Imply?|
finance.yahoo.com - January 24 at 3:45 PM
|Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.|
finance.yahoo.com - January 23 at 4:58 PM
|Here's Why the 2 Latest Hemispherx BioPharma Announcements Are Important|
finance.yahoo.com - January 19 at 3:49 PM
|Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility|
finance.yahoo.com - January 17 at 11:18 AM
|Hemispherx Enhances Manufacturing Efficiency of Ampligen - Nasdaq|
www.nasdaq.com - January 12 at 11:19 AM
|Hemispherx Enhances Manufacturing Efficiency of Ampligen - GlobeNewswire (press release)|
globenewswire.com - January 11 at 3:40 PM
|Hemispherx BioPharma, Inc (HEB) Short Interest Update|
www.americanbankingnews.com - January 11 at 2:36 AM
|Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV - GlobeNewswire (press release)|
globenewswire.com - January 4 at 3:39 PM
|Hemispherx Biopharma, Inc. Discusses Clinical Development and Approval in Argentina in New SNNLive Video Interview on StockNewsNow.com|
finance.yahoo.com - January 3 at 10:50 AM
|Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV|
finance.yahoo.com - January 2 at 11:06 AM
|Hemispherx Biopharma, Inc. to Present at Biotech Showcase ... - GlobeNewswire (press release)|
globenewswire.com - December 30 at 3:39 PM
|Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 2.1%|
www.americanbankingnews.com - December 29 at 1:28 AM
|ETFs with exposure to Hemispherx Biopharma, Inc. : December 26, 2017|
finance.yahoo.com - December 26 at 12:41 PM
|Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer - GlobeNewswire (press release)|
globenewswire.com - December 20 at 3:38 PM
|Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer|
finance.yahoo.com - December 20 at 11:27 AM
|ETFs with exposure to Hemispherx Biopharma, Inc. : December 15, 2017|
finance.yahoo.com - December 15 at 3:43 PM
|Short Interest in Hemispherx Biopharma, Inc. (HEB) Increases By 7.0%|
www.americanbankingnews.com - December 11 at 7:58 PM
|ETFs with exposure to Hemispherx Biopharma, Inc. : December 5, 2017|
finance.yahoo.com - December 5 at 1:02 PM
|Hemispherx Biopharma, Inc. (HEB) Short Interest Up 4.2% in November|
www.americanbankingnews.com - November 28 at 1:04 AM
|Hemispherx BioPharma, Inc (HEB) Releases Earnings Results|
www.americanbankingnews.com - November 16 at 6:44 PM
|Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV - GlobeNewswire (press release)|
globenewswire.com - November 16 at 4:02 PM
|Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV|
feeds.benzinga.com - November 15 at 9:57 AM
|HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?|
finance.yahoo.com - November 14 at 3:51 PM
Hemispherx BioPharma (NYSEAMERICAN:HEB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Hemispherx BioPharma (NYSEAMERICAN:HEB) Income Statement, Balance Sheet and Cash Flow Statement
Hemispherx BioPharma (NYSEAMERICAN HEB) Stock Chart for Sunday, February, 25, 2018